By Jennifer Maffia, Owner of Advanced Recruiting Partners 

If you only look at surface level employment data, the life sciences job market appears relatively stable. Roles are being filled. Companies are hiring. Professionals are working. 

But underneath that stability, there is a quieter shift happening, one that many hiring managers and candidates are feeling in real time. More biopharma professionals are accepting roles that do not fully reflect their experience, skill set, or long-term career trajectory. 

They are employed, but they are under-leveled, underutilized, and in many cases, intentionally settling. 

From where I sit, working closely with both clients and candidates across the industry, this is not an isolated trend. It is becoming a defining characteristic of the current talent landscape. 

What “Overqualified” Looks Like Right Now 

Overqualification in today’s market is not always obvious on paper, but it shows up in consistent patterns. 

We are seeing senior level professionals stepping into mid level roles just to remain active in the workforce. Candidates with advanced degrees and highly specialized experience are accepting positions that only use a portion of their expertise. Leaders who previously managed teams or departments are moving back into individual contributor roles. 

In many cases, this is not about capability. It is about access. 

The roles that match their full experience level are fewer, more competitive, or simply not being opened at the same pace as before. 

What Is Driving This Shift 

There is no single cause behind this trend. It is the result of several market forces converging at once. 

First, market volatility continues to reshape hiring demand. Funding slowdowns, pipeline reprioritization, and restructuring across biotech and pharma have reduced the number of senior and strategic roles available. Even highly qualified candidates are finding themselves competing in a much tighter market. 

Second, candidates themselves are becoming more risk averse. After experiencing layoffs or prolonged job searches, many professionals are prioritizing stability over title, compensation growth, or ideal alignment. The mindset has shifted from “what is my next step forward” to “what keeps me secure right now.” 

At the same time, employers are hiring more cautiously. There is a growing tendency to look for very specific, narrowly aligned candidates, often with concerns about hiring someone perceived as a flight risk. If a candidate appears overqualified, some organizations worry they will leave as soon as a better opportunity comes along. 

Finally, the rise of contract and project-based work is playing a role. Highly skilled professionals are increasingly open to, or reliant on, contract roles that may not fully reflect their level, but offer a way to stay engaged in the industry. 

The Hidden Costs of Underemployment 

While this trend may feel like a practical compromise in the short term, it carries long term implications for both professionals and organizations. 

For candidates, there is a real risk of skill misalignment. When someone consistently operates below their level, they may not be developing the experience needed for their next step. Over time, this can impact earning potential, confidence, and career momentum. It can also lead to disengagement, especially when individuals feel their capabilities are not being fully utilized. 

For employers, the risks are different but equally important. Overqualified hires often bring significant value, but they can also be more likely to leave once the market improves or the right opportunity presents itself. This creates potential retention challenges. 

There is also the issue of underutilized talent. When highly experienced professionals are placed in roles that do not fully leverage their expertise, organizations are not maximizing the value of the talent they have worked hard to secure. 

Why This Matters for Biopharma Leaders 

In an industry where innovation, speed, and precision are critical, talent alignment is not a minor detail. It is a competitive advantage. 

When professionals are not operating at their full capacity, it can slow down progress across clinical development, regulatory strategy, and commercialization efforts. It can also impact team dynamics, especially when there is a mismatch between experience levels and role expectations. 

Leaders who recognize this shift have an opportunity to think more strategically about how they structure roles and engage talent, even in a constrained market. 

What Forward Thinking Organizations Are Doing 

The organizations navigating this most effectively are not ignoring the trend. They are adapting to it. 

Some are designing roles with more flexibility, allowing overqualified candidates to contribute beyond the traditional scope of the position. Others are creating clearer pathways for growth, even if the initial role is not perfectly aligned with a candidate’s full experience. 

Transparency is also playing a key role. When companies are upfront about the scope of a role, potential trajectory, and business context, candidates are better able to make informed decisions and are more likely to stay engaged. 

We are also seeing a shift away from overly rigid job descriptions. Instead of focusing solely on years of experience or narrow criteria, leading organizations are prioritizing impact, adaptability, and long term potential. 

Guidance for Candidates Navigating This Market 

For professionals, the reality of this market requires a balance between practicality and long term strategy. 

Taking a role that is not a perfect fit does not have to be a setback, but it should be a conscious decision. It is important to stay connected to your long term goals and continue building skills, even within a role that may feel like a step back. 

Positioning also matters. How you frame your experience, both during and after these roles, can influence how future employers perceive your trajectory. 

Perhaps most importantly, partnering with a recruiter who understands the nuances of the biopharma market can make a significant difference. The right guidance can help you identify opportunities that align not just with what is available, but with where you want to go next. 

A Market Signal Worth Paying Attention To 

Underemployment in biopharma is not just a temporary inconvenience. It is a signal. 

It reflects a shift in how organizations are hiring, how professionals are making decisions, and how the industry is adapting to ongoing uncertainty. 

The companies that will come out ahead are the ones that look beyond short-term hiring needs and think more intentionally about talent alignment, development, and retention. 

Because in a market where so many professionals are willing to settle, the real opportunity lies in ensuring they do not have to. 

About Jennifer Maffia 
With over 20 years of experience in clinical staffing, Jennifer Maffia connects pharmaceutical, biotech, and life sciences companies with top-tier clinical talent. She is known for building lasting client relationships, supporting tenured recruiters, and driving impactful hiring strategies. Through industry partnerships and active board involvement, Jennifer remains committed to advancing the life sciences field and improving patient outcomes.